Bowie and Trauner
acidified to pH 2 with 1 N hydrochloric acid and then extracted
with CH2Cl2 (3 × 25 mL). The combined organic extracts were
dried, filtered, and concentrated in vacuo to give a yellow oil. The
product was subsequently purified by column chromatography (35%
EtOAc in hexanes) to afford 859 mg (99%) of 21 as a foamy solid:
IR (film) 3055, 2987, 1653 cm-1; 1H NMR δ 9.33 (s, 1H), 6.90 (d,
J ) 5.0 Hz, 1H), 6.04 (d, J ) 5.0 Hz, 1H), 4.31 (m, 2H), 2.33-2.21
(m, 2H), 2.04-1.92 (m, 4H), 1.76 (m, 1H), 1.67 (m, 3H), 0.80 (t,
J ) 6.0 Hz, 3H); 13C NMR δ 179.1, 178.7, 146.3, 130.7, 125.1,
107.7, 45.4, 38.1, 34.5, 33.2, 29.6, 28.8, 26.6, 19.5, 8.5; HRMS
(EI+) m/z (M + H+) calcd for C14H19NO3 250.1443, found
250.1443.
Lactam 26. Iodide 22 (53.5 mg, 0.11 mmol), potassium
carbonate (29.9 mg, 0.22 mmol), 2-dicyclohexylphosphino-2′-(N,N-
dimethylamino)biphenyl (4.3 mg, 0.11 mmol), and palladium
acetate (2.5 mg, 0.11 mmol) were placed in a flame-dried vial. The
vial was flushed with nitrogen, N,N-dimethylacetamide (DMA, 1.8
mL) was added, and the solution was heated to 135 °C. After 18 h,
the solution was allowed to cool, and the solvent was removed by
rotary evaporation under high vacuum. The resulting black residue
was diluted with CH2Cl2 and passed through a plug of silica gel.
The product was purified by column chromatography (25% EtOAc
in hexanes) to afford 17.3 mg (43%) of 26 as a white solid: IR
1
(film) 1653 cm -1; H NMR δ 9.37 (s, 1 H), 7.43 (m, 1 H), 7.35
(m, 3 H) 6.57 (s, 1 H), 5.17 (d, J ) 10.0 Hz, 1 H), 4.75 (m, 1 H),
4.30 (d, J ) 10.0 Hz, 1 H), 3.93 (m, 1 H), 3.26 (s, 3 H), 2.50 (m,
2 H), 2.17 (m, 2 H), 1.92 (m, 1 H), 1.73 (m, 1 H), 1.55 (m, 4 H),
0.86 (t, J ) 10.0 Hz, 3H); 13C NMR δ 178.6, 175.3, 142.5, 141.4,
136.9, 131.3, 129.9, 129.1, 127.5, 127.1, 125.6, 120.0, 78.9, 56.8,
46.3, 39.7, 36.8, 31.9, 29.8, 29.4, 18.5, 8.2; HRMS (EI+) m/z (M
+ Na+) calcd for C22H26N2O3 389.1841, found 389.1842.
Rhazinal 2. To a solution of lactam 26 (16 mg, 0.044 mmol) in
CH2Cl2 (2.2 mL) at -78 °C was added boron trichloride (0.44 mL,
1.0 M, 0.44 mmol) dropwise via syringe over 2 min. After 2.5 h at
-78 °C, the reaction was quenched with a saturated NaHCO3
solution (5 mL), and the mixture was extracted with EtOAc (3 ×
15 mL), dried, and concentrated down. The crude solid was
dissolved in MeOH (2.2 mL) and Et3N (0.14 mL) and the solution
was heated at 50 °C for 2 h. The product was purified by column
chromatography (30% EtOAc in hexanes) to give 8.0 mg (45%)
of 1 as a white solid: mp 230-234 °C; IR (film) 3510, 1662 cm
-1; 1H NMR δ 9.39 (s, 1 H), 7.41 (m, 1 H), 7.37 (m, 3 H) 6.74 (br
s, 1 H), 6.55 (s, 1 H), 4.78 (m, 1 H), 3.98 (m, 1 H), 2.50 (m, 2 H),
2.19 (m, 1 H), 2.04 (m 1 H), 1.97 (m, 1 H), 1.79 (m, 1 H), 1.55
(m, 3 H), 1.24 (m, 1 H), 0.71 (t, J ) 7.5 Hz, 3 H); 13C NMR δ
178.6, 176.57, 141.4, 138.2, 137.5, 131.3, 130.1, 129.0, 127.8,
127.1, 125.6, 120.4, 46.3, 39.6, 36.6, 31.9, 29.8, 28.0, 18.5, 8.1;
HRMS (EI+) m/z (M + H+) calcd for C20H22N2O2 323.1759, found
323.1755.
3-(8-Ethyl-3-formyl-5,6,7,8-tetrahydroindolizin-8-yl)-N-(2-
iodophenyl)propionamide 3b. To a solution of acid 21 (301 mg,
1.20 mmol) in CH2Cl2 (6 mL) were added 2-chloro-1-methyl-
pyridinium iodide (371 mg, 1.45 mmol), 2-iodoaniline (317 mg,
1.45 mmol), and Et3N (0.33 mL, 2.4 mmol). The mixture was heated
at reflux for an additional 15 h, allowed to cool, poured into water
(40 mL), and extracted with CH2Cl2 (3 × 20 mL). The combined
organic extracts were dried, filtered, and concentrated. The product
was purified by column chromatography (25% EtOAc in hexanes)
to furnish 299 mg (55%) of 3 as a foamy solid: IR (film) 3300,
1
2946, 1724, 1654 cm-1; H NMR δ 9.42 (m, 1 H), 8.13 (d, J )
10.0 Hz, 1 H), 7.74 (d, J ) 5.0 Hz, 1 H) 7.42 (br s, 1 H), 7.30 (t,
J ) 5 Hz, 1 H), 6.89 (d, J ) 5.0 Hz, 1 H), 6.82 (t, J ) 5 Hz, 1 H),
6.08 (d, J ) 5.0 Hz, 1 H), 4.37 (m, 1H), 4.28 (m, 1H), 2.34 (m, 1
H), 2.23 (m, 1 H), 2.03 (m, 2 H), 1.97 (m, 2 H), 1.70 (m, 4 H),
0.86 (t, J ) 10 Hz, 3H); 13C NMR δ 178.6, 171.0, 146.1, 138.8,
138.1, 130.9, 129.3, 126.1, 124.7, 122.3, 107.5, 90.3, 45.5, 38.3,
35.3, 33.6, 33.2, 28.8, 19.6, 8.6; HRMS (EI+) m/z (M + H+) calcd
for C20H23IN2O2 451.0883, found 451.0891.
3-(8-Ethyl-3-formyl-5,6,7,8-tetrahydroindolizin-8-yl)-N-(2-
iodophenyl)-N-methoxymethylpropionamide 22. To a solution
of the amide 3b (234 mg, 0.520 mmol) in THF (2.66 mL) at -78
°C was added a solution of sodium bis(trimethylsilyl)amide in THF
(0.34 mL, 2.0 M, 0.68 mmol) dropwise via syringe. After 2 h at 0
°C, a solution of chloromethyl methyl ether in THF (1.0 mL, 0.70
M, 0.70 mmol) was added dropwise. After an additional 10 min,
the mixture was allowed to warm to room temperature over 1 h,
diluted with water (15 mL), and extracted with EtOAc (3 × 20
mL). The product was purified by column chromatography (30%
EtOAc in hexanes) to yield 191 mg (75%) of 22 as a yellowish
solid: IR (film) 3055, 2364, 1722, 1653 cm-1; 1H NMR δ 9.37 (s,
1 H), 7.93 (m, 1 H), 7.37 (t, J ) 8.0 Hz, 1 H) 7.22 (d, J ) 8.0 Hz,
0.5 H), 7.15 (d, J ) 8.0 Hz, 0.5 H), 7.07 (t, J ) 8.0 Hz, 1 H), 6.77
(m, 1 H), 5.80 (m, 1 H), 5.55 (m, 1H), 4.32 (m, 1H), 4.22-4.11
(m, 2 H), 3.42 (s, 3 H), 1.98-1.78 (m, 6 H), 1.61 (m, 1 H), 1.45
(m, 3 H), 0.86 (t, J ) 8.0 Hz, 3H); 13C NMR δ 178.4, 173.7, 146.2,
143.2, 140.1, 130.8, 130.6, 130.2, 129.6, 124.5, 107.5, 100.5, 90.3,
78.1, 57.0, 45.3, 38.1, 38.0, 35.1, 34.9, 35.3, 33.1, 32.9, 30.1, 30.0,
28.9, 28.7, 19.5, 8.5; HRMS (EI+) m/z (M + Na+) calcd for
C22H27IN2O3 517.0964, found 517.0960.
Acknowledgment. We acknowledge financial support from
Novartis, Roche, and the National Institutes of Health (Minority
Supplement). We thank Dr. Frederick J. Hollander and Dr. Allen
G. Oliver for the crystal structure determination of compound
26.
Supporting Information Available: Experimental proce-
dures for the preparation of 5, 7-16, and 3a and the X-ray
structure of 26. Copies of NMR spectra for all new compounds
are available (including X-ray structure CCDC 697745). This
material is available free of charge via the Internet at
JO801791J
1586 J. Org. Chem. Vol. 74, No. 4, 2009